Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Provided By GlobeNewswire
Last update: Dec 19, 2024
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs.
Read more at globenewswire.com3.89
-0.14 (-3.47%)
Find more stocks in the Stock Screener
LXEO Latest News and Analysis
3 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
